ClinicalTrials.Veeva

Menu

HIFU for Focal Ablation of Prostate Tissue: an Observational Study

University of California, Los Angeles (UCLA) logo

University of California, Los Angeles (UCLA)

Status

Enrolling

Conditions

Prostate Cancer

Treatments

Device: Sonablate HIFU device

Study type

Observational

Funder types

Other

Identifiers

NCT03620786
16-000904

Details and patient eligibility

About

The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.

Full description

This observational study will serve to collect data from medical record review and questionnaires before and after High Intensity Focused Ultrasound (HIFU) for focal ablation of prostate tissue. The subject will have already undergone or opted to receive the HIFU procedure as part of standard of care in order to participate in this study.

Enrollment

100 estimated patients

Sex

Male

Ages

40 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age 40 years to 85 years
  2. Subject has elected or already undergone HIFU therapy as their standard of care treatment methodand declined alternative treatment (active surveillance, radical prostatectomy, radiation therapy, cryosurgery and hormone therapy)
  3. PSA ≤ 20
  4. Prostate volume of ≤ 70 cc
  5. Ability to complete informed consent form

Exclusion criteria

  1. Prior treatment for prostate cancer (with the exception of androgen deprivation therapy)
  2. Medical contraindication to follow-up mpMRI or prostate biopsy
  3. Unable to tolerate general or regional anesthesia
  4. Positive bone scan (only if bone scan has been done or clinically indicated. Bone scan does not need to be performed for study eligibility determination.)

Trial design

100 participants in 1 patient group

HIFU Study Participants
Description:
Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received the HIFU procedure as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study. The HIFU device currently used in this standard-of-care procedure at UCLA is the Sonablate 450 HIFU System.
Treatment:
Device: Sonablate HIFU device

Trial contacts and locations

1

Loading...

Central trial contact

Merdie Delfin, MSN, NP; Michelle Cardenas, MSN, RN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems